

CLINICAL BENEFITS OF HIFU


Benefits	HIFU	Rad. Surgery	Ext Rad	Brachy
Non-Invasive	Yes	No	Yes	No
Early Feedback	Yes	Yes	No	No
Quality of Life	High	Low	Med	Med
Repeatable	Yes	No	No	No

Negative biopsy results observed following HIFU

Study	Tx	n	Pretreatment PSA (ng/ml)	Gleason	Clinical T Stage	Median follow-up	% negative biopsy
Uchida et al. 2002	HIFU	33	Mean 10.97	29% 2-4 66% 5-7	T1b-T2	13.2 mos	100%
Uchida et al. 2004	HIFU	214	Mean 16.1	21% 2-4 71% 5-7 8% 8-10	T1c-T2b	20.6 mos	95%

Rewcastle, John C. "High Intensity Focused Ultrasound for Prostate Cancer: Clinical Results and Technological Evolution" 2004.

Comparison of negative biopsy results of brachytherapy (Brachy), 3-dimensional conformal radiation therapy (3D-CRT), external beam radiation therapy (XRT), cryoablation (CRYO) and HIFU.



Rewcastle, John C. "High Intensity Focused Ultrasound for Prostate Cancer: Clinical Results and Technological Evolution" 2004.

"Early follow-up would suggest that transrectal HIFU therapy could be used to ablate localized prostate cancer with an acceptable incidence of adverse events accompanied by a relatively high CR (Complete Recovery) rate and the ability to deliver repeated HIFU treatments."

Dr. Toyoakai Uchida, *Urology Journal*

T. UCHIDA STUDY

	Results
Patients Treated	86
No. Treatments	100
Pre-PSA <10ng/ml	94% CR
Pre-PSA <20ng/ml	84% CR
Mean Follow Up	18.5 Months

*CR = Complete Recovery following ASTRO guidelines of three successive PSA increases



**FOCUS
SURGERY**

Focused on Results